Children treated with pegylated interferon alfa-2a±ribavirin for chronic hepatitis c

Kathleen B. Schwarz, Jean Molleston, Maureen M. Jonas, Jessica Wen, Karen F. Murray, Philip Rosenthal, Regino P. Gonzalez-Peralta, Steven J. Lobritto, Douglas Mogul, Vedran Pavlovic, Charles Warne, Cynthia Wat, Bruce Thompson

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Objectives: No long-term data have been published on the durability of response following pegylated interferon (PegIFN) treatment in children with chronic hepatitis C. This prospective, multicenter, long-term follow-up (LTFU) study aimed to assess long-term durability of sustained virological response (SVR), long-term safety and tolerability, and the association between IL28B genotype and treatment response, in children previously treated with PegIFN alfa-2a±ribavirin (RBV) in the PEDS-C trial. Methods: A total of 93 patients were assessed for enrollment, and 38 enrolled in the study. Patients attended 2 study visits: 5 (mean 5.6, range 4.1-6.6) and 6 (6.6, 5.1-7.7) years after treatment cessation. Standardized medical history, physical examination, and laboratory testing were performed at these visits. Reminder telephone calls were conducted at 4 and 8 months after the initial visit. Results: The LTFU cohort was the representative of the original PEDS-C cohort because both baseline and treatment characteristics were comparable. Of the 38 participants, 21 achieved SVR (responders) during the PEDS-C trial and 17 had not (nonresponders). All 21 responders maintained undetectable hepatitis C virus RNA during the LTFU (4.4-7.0 years after achieving SVR) in contrast to the nonresponders who demonstrated persistent viremia. IL28B CC genotype was associated with SVR (67% vs 30% in non-CC, P =0.028). Conclusion: Long-term durability of SVR is excellent following PegIFN alfa-2a treatment in children with chronic hepatitis C; SVR is higher in those with IL28B CC versus non-CC.

Original languageEnglish (US)
Pages (from-to)93-96
Number of pages4
JournalJournal of Pediatric Gastroenterology and Nutrition
Volume62
Issue number1
DOIs
StatePublished - 2016

Fingerprint

Chronic Hepatitis
Interferon-alpha
Chronic Hepatitis C
Genotype
Withholding Treatment
Viremia
Therapeutics
Telephone
Hepacivirus
Interferons
Physical Examination
RNA
Safety

Keywords

  • antiviral therapy
  • long-term follow-up
  • pediatric viral hepatitis
  • PEDS-C study

ASJC Scopus subject areas

  • Gastroenterology
  • Pediatrics, Perinatology, and Child Health

Cite this

Children treated with pegylated interferon alfa-2a±ribavirin for chronic hepatitis c. / Schwarz, Kathleen B.; Molleston, Jean; Jonas, Maureen M.; Wen, Jessica; Murray, Karen F.; Rosenthal, Philip; Gonzalez-Peralta, Regino P.; Lobritto, Steven J.; Mogul, Douglas; Pavlovic, Vedran; Warne, Charles; Wat, Cynthia; Thompson, Bruce.

In: Journal of Pediatric Gastroenterology and Nutrition, Vol. 62, No. 1, 2016, p. 93-96.

Research output: Contribution to journalArticle

Schwarz, KB, Molleston, J, Jonas, MM, Wen, J, Murray, KF, Rosenthal, P, Gonzalez-Peralta, RP, Lobritto, SJ, Mogul, D, Pavlovic, V, Warne, C, Wat, C & Thompson, B 2016, 'Children treated with pegylated interferon alfa-2a±ribavirin for chronic hepatitis c', Journal of Pediatric Gastroenterology and Nutrition, vol. 62, no. 1, pp. 93-96. https://doi.org/10.1097/MPG.0000000000000929
Schwarz, Kathleen B. ; Molleston, Jean ; Jonas, Maureen M. ; Wen, Jessica ; Murray, Karen F. ; Rosenthal, Philip ; Gonzalez-Peralta, Regino P. ; Lobritto, Steven J. ; Mogul, Douglas ; Pavlovic, Vedran ; Warne, Charles ; Wat, Cynthia ; Thompson, Bruce. / Children treated with pegylated interferon alfa-2a±ribavirin for chronic hepatitis c. In: Journal of Pediatric Gastroenterology and Nutrition. 2016 ; Vol. 62, No. 1. pp. 93-96.
@article{6b8f57cea9914ef4ada641ad2d026452,
title = "Children treated with pegylated interferon alfa-2a±ribavirin for chronic hepatitis c",
abstract = "Objectives: No long-term data have been published on the durability of response following pegylated interferon (PegIFN) treatment in children with chronic hepatitis C. This prospective, multicenter, long-term follow-up (LTFU) study aimed to assess long-term durability of sustained virological response (SVR), long-term safety and tolerability, and the association between IL28B genotype and treatment response, in children previously treated with PegIFN alfa-2a±ribavirin (RBV) in the PEDS-C trial. Methods: A total of 93 patients were assessed for enrollment, and 38 enrolled in the study. Patients attended 2 study visits: 5 (mean 5.6, range 4.1-6.6) and 6 (6.6, 5.1-7.7) years after treatment cessation. Standardized medical history, physical examination, and laboratory testing were performed at these visits. Reminder telephone calls were conducted at 4 and 8 months after the initial visit. Results: The LTFU cohort was the representative of the original PEDS-C cohort because both baseline and treatment characteristics were comparable. Of the 38 participants, 21 achieved SVR (responders) during the PEDS-C trial and 17 had not (nonresponders). All 21 responders maintained undetectable hepatitis C virus RNA during the LTFU (4.4-7.0 years after achieving SVR) in contrast to the nonresponders who demonstrated persistent viremia. IL28B CC genotype was associated with SVR (67{\%} vs 30{\%} in non-CC, P =0.028). Conclusion: Long-term durability of SVR is excellent following PegIFN alfa-2a treatment in children with chronic hepatitis C; SVR is higher in those with IL28B CC versus non-CC.",
keywords = "antiviral therapy, long-term follow-up, pediatric viral hepatitis, PEDS-C study",
author = "Schwarz, {Kathleen B.} and Jean Molleston and Jonas, {Maureen M.} and Jessica Wen and Murray, {Karen F.} and Philip Rosenthal and Gonzalez-Peralta, {Regino P.} and Lobritto, {Steven J.} and Douglas Mogul and Vedran Pavlovic and Charles Warne and Cynthia Wat and Bruce Thompson",
year = "2016",
doi = "10.1097/MPG.0000000000000929",
language = "English (US)",
volume = "62",
pages = "93--96",
journal = "Journal of Pediatric Gastroenterology and Nutrition",
issn = "0277-2116",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Children treated with pegylated interferon alfa-2a±ribavirin for chronic hepatitis c

AU - Schwarz, Kathleen B.

AU - Molleston, Jean

AU - Jonas, Maureen M.

AU - Wen, Jessica

AU - Murray, Karen F.

AU - Rosenthal, Philip

AU - Gonzalez-Peralta, Regino P.

AU - Lobritto, Steven J.

AU - Mogul, Douglas

AU - Pavlovic, Vedran

AU - Warne, Charles

AU - Wat, Cynthia

AU - Thompson, Bruce

PY - 2016

Y1 - 2016

N2 - Objectives: No long-term data have been published on the durability of response following pegylated interferon (PegIFN) treatment in children with chronic hepatitis C. This prospective, multicenter, long-term follow-up (LTFU) study aimed to assess long-term durability of sustained virological response (SVR), long-term safety and tolerability, and the association between IL28B genotype and treatment response, in children previously treated with PegIFN alfa-2a±ribavirin (RBV) in the PEDS-C trial. Methods: A total of 93 patients were assessed for enrollment, and 38 enrolled in the study. Patients attended 2 study visits: 5 (mean 5.6, range 4.1-6.6) and 6 (6.6, 5.1-7.7) years after treatment cessation. Standardized medical history, physical examination, and laboratory testing were performed at these visits. Reminder telephone calls were conducted at 4 and 8 months after the initial visit. Results: The LTFU cohort was the representative of the original PEDS-C cohort because both baseline and treatment characteristics were comparable. Of the 38 participants, 21 achieved SVR (responders) during the PEDS-C trial and 17 had not (nonresponders). All 21 responders maintained undetectable hepatitis C virus RNA during the LTFU (4.4-7.0 years after achieving SVR) in contrast to the nonresponders who demonstrated persistent viremia. IL28B CC genotype was associated with SVR (67% vs 30% in non-CC, P =0.028). Conclusion: Long-term durability of SVR is excellent following PegIFN alfa-2a treatment in children with chronic hepatitis C; SVR is higher in those with IL28B CC versus non-CC.

AB - Objectives: No long-term data have been published on the durability of response following pegylated interferon (PegIFN) treatment in children with chronic hepatitis C. This prospective, multicenter, long-term follow-up (LTFU) study aimed to assess long-term durability of sustained virological response (SVR), long-term safety and tolerability, and the association between IL28B genotype and treatment response, in children previously treated with PegIFN alfa-2a±ribavirin (RBV) in the PEDS-C trial. Methods: A total of 93 patients were assessed for enrollment, and 38 enrolled in the study. Patients attended 2 study visits: 5 (mean 5.6, range 4.1-6.6) and 6 (6.6, 5.1-7.7) years after treatment cessation. Standardized medical history, physical examination, and laboratory testing were performed at these visits. Reminder telephone calls were conducted at 4 and 8 months after the initial visit. Results: The LTFU cohort was the representative of the original PEDS-C cohort because both baseline and treatment characteristics were comparable. Of the 38 participants, 21 achieved SVR (responders) during the PEDS-C trial and 17 had not (nonresponders). All 21 responders maintained undetectable hepatitis C virus RNA during the LTFU (4.4-7.0 years after achieving SVR) in contrast to the nonresponders who demonstrated persistent viremia. IL28B CC genotype was associated with SVR (67% vs 30% in non-CC, P =0.028). Conclusion: Long-term durability of SVR is excellent following PegIFN alfa-2a treatment in children with chronic hepatitis C; SVR is higher in those with IL28B CC versus non-CC.

KW - antiviral therapy

KW - long-term follow-up

KW - pediatric viral hepatitis

KW - PEDS-C study

UR - http://www.scopus.com/inward/record.url?scp=84952690737&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84952690737&partnerID=8YFLogxK

U2 - 10.1097/MPG.0000000000000929

DO - 10.1097/MPG.0000000000000929

M3 - Article

C2 - 26284539

AN - SCOPUS:84952690737

VL - 62

SP - 93

EP - 96

JO - Journal of Pediatric Gastroenterology and Nutrition

JF - Journal of Pediatric Gastroenterology and Nutrition

SN - 0277-2116

IS - 1

ER -